Figure 1.
Factors predicting outcome in patients who relapse after a RIC allograft for AML. Prognostic groups as defined by risk factors available at time of relapse (longer interval between hematopoietic SCT and relapse, a lower BM infiltration by leukemic blasts, and having no history of acute GVHD after hematopoietic SCT) were associated with superior outcome. Used with permission from Schmid et al.3